Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Blood (2023) 142 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2023-186599

Published: 2023

Journal Articles

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Blood (2023) 142 (Supplement 1): 6742.

https://doi.org/10.1182/blood-2023-185792

Published: 2023

Journal Articles

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Blood (2022) 140 (Supplement 1): 4379–4381.

https://doi.org/10.1182/blood-2022-158484

Published: 2022

Journal Articles

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Blood (2022) 140 (Supplement 1): 4452–4453.

https://doi.org/10.1182/blood-2022-166870

Published: 2022

Journal Articles

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Laure Vincent, Anne Charvet-Rumpler, Lotfi Benboubker, Claire Calmettes, Anne-Marie Stoppa, Kamel Laribi, Lauriane Clement Filliatre, Fressia Honeyman, Richez Valentine, Cyrille Hulin, Frédéric Maloisel, Margaret Macro, Lionel Karlin, Vanessa Barué, Christos Chouaid, Hacène Zerazhi, Xavier Leleu

Blood (2022) 140 (Supplement 1): 4312–4314.

https://doi.org/10.1182/blood-2022-157942

Published: 2022

Journal Articles

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 896.

https://doi.org/10.1182/blood-2021-147915

Published: 2021

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2021) 137 (26): 3616–3628.

https://doi.org/10.1182/blood.2020008787

Published: 2021

Includes: Supplemental data

Journal Articles

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

Thomas Chalopin, Nicolas Vallet, MD, Marlene Ochmann, MD, Mourad Tiab, Pascal Godmer, Carole Barin, Olivier Theisen, MD, Olivier Herault, MD PhD, Emmanuel Gyan, MD PhD, Lotfi Benboubker, MD, Philippe Moreau, MD, Herve Avet-Loiseau, Cyrille Touzeau

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-139436

Published: 2020

Journal Articles

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

Lauriane Clement-Filliatre, MD, Lotfi Benboubker, MD, Anne-Marie Stoppa, Philippe Rodon, MD, Kamel Laribi, MD, Laure Vincent, Philippe Collet, Valentine Richez, MD, Anne Charvet-Rumpler, Hacene Zerazhi, MD, Cyrille Hulin, MD, Frederic Maloisel, MD PhD, Margaret Macro, Lionel Karlin, MD, Nathalie Texier, Christos Chouaid, Xavier Leleu, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-133807

Published: 2020

Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1866.

https://doi.org/10.1182/blood-2019-123483

Published: 2019

Journal Articles

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Sagar Lonial, Joaquin Martinez-Lopez, MD PhD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD, Albert Oriol, Paula Rodriguez Otero, Luis Pineiro, Andrzej Jakubowiak, MD PhD, Yunsi Olyslager, Jianping Wang, Ivo Nnane, Jon Ukropec, PhD, Martin Shreeve, Ming Qi, MD PhD, Philippe Moreau, MD

Blood (2019) 134 (Supplement_1): 1876.

https://doi.org/10.1182/blood-2019-123539

Published: 2019

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Saad Z. Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesus San-Miguel

Blood (2019) 134 (8): 668–677.

https://doi.org/10.1182/blood.2019000667

Published: 2019

Includes: Supplemental data

Journal Articles

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Paula Rodriguez-Otero, Luis Pineiro, Andrzej Jakubowiak, Carla de Boer, Jianping Wang, Pamela L. Clemens, Jon Ukropec, Jordan Schecter, Sagar Lonial, Philippe Moreau

Blood (2019) 134 (5): 421–431.

https://doi.org/10.1182/blood.2019000722

Published: 2019

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pamela L Clemens, PhD, Steven Xu, PhD, Melody Luo, PhD, Ajai Chari, MD, Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Jesus F San-Miguel, MD PhD, X. Yu-Nien Sun, Andrew Farnsworth, Tara Masterson, Peter Hellemans, Ming Qi, MD PhD, Hareth Nahi, MD PhD

Blood (2018) 132 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2018-99-113161

Published: 2018

Journal Articles

Pomalidomide 3rd Line Versus 4 th Line for RRMM

Blood (2018) 132 (Supplement 1): 5633.

https://doi.org/10.1182/blood-2018-99-115449

Published: 2018

NARROW

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pomalidomide 3rd Line Versus 4 th Line for RRMM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only